Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.66 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.56 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.56 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21616836 | 0.83 | TMEM97 (0.58) | TMEM97SIGMAR1 | |
| SCHEMBL6408326 | 0.80 | TMEM97 (0.72) | TMEM97NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL2061822 | 0.79 | IDO1 (0.64) | TMEM97IDO1CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL8561633 | 0.78 | IDO1 (0.59) | IDO1CDYL2CDYLCDY1; CDY1BNOS3 | |
| SCHEMBL12124425 | 0.76 | TMEM97 (0.66) | TMEM97NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL10507200 | 0.76 | IDO1 (0.63) | IDO1CDYL2CDYLCDY1; CDY1BALDH1A1 | |
| SCHEMBL5423077 | 0.74 | IDO1 (0.62) | IDO1CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL12124424 | 0.74 | SIGMAR1 (0.83) | TMEM97NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL11135151 | 0.74 | KMO (0.56) | IDO1CDYL2CDYLCDY1; CDY1BALDH1A1 | |
| SCHEMBL18171790 | 0.73 | IDO1 (0.79) | IDO1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1465630-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003057220-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | HTR2C, HTR3C, HTR5A | TMEM97 244/4885IDO1 785/4885CDYL2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.